PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Targeted therapy - Market size and forecast 2018-2023 Chemotherapy - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Emergence of pipeline molecules Presence of reimbursement and patient assistance programs Advent of novel therapies PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AstraZeneca Plc Bristol-Myers Squibb Co. Eli Lilly and Co. F. Hoffmann-La Roche Ltd. Merck & Co. Inc. Mylan NV Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Targeted therapy - Year-over-year growth 2019-2023 (%) Exhibit 22: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Adverse effects of common chemotherapy drugs Exhibit 43: Impact of drivers and challenges Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendors covered Exhibit 47: Vendor classification Exhibit 48: Market positioning of vendors Exhibit 49: AstraZeneca Plc - Vendor overview Exhibit 50: AstraZeneca Plc - Business segments Exhibit 51: AstraZeneca Plc - Organizational developments Exhibit 52: AstraZeneca Plc - Geographic focus Exhibit 53: AstraZeneca Plc - Key offerings Exhibit 54: AstraZeneca Plc - Key customers Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview Exhibit 56: Bristol-Myers Squibb Co. - Business segments Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus Exhibit 59: Bristol-Myers Squibb Co. - Key offerings Exhibit 60: Bristol-Myers Squibb Co. - Key customers Exhibit 61: Eli Lilly and Co. - Vendor overview Exhibit 62: Eli Lilly and Co. - Business segments Exhibit 63: Eli Lilly and Co. - Organizational developments Exhibit 64: Eli Lilly and Co. - Geographic focus Exhibit 65: Eli Lilly and Co. - Segment focus Exhibit 66: Eli Lilly and Co. - Key offerings Exhibit 67: Eli Lilly and Co. - Key customers Exhibit 68: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 69: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 70: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 71: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 72: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 73: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 74: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 75: Merck & Co. Inc. - Vendor overview Exhibit 76: Merck & Co. Inc. - Business segments Exhibit 77: Merck & Co. Inc. - Organizational developments Exhibit 78: Merck & Co. Inc. - Geographic focus Exhibit 79: Merck & Co. Inc. - Segment focus Exhibit 80: Merck & Co. Inc. - Key offerings Exhibit 81: Merck & Co. Inc. - Key customers Exhibit 82: Mylan NV - Vendor overview Exhibit 83: Mylan NV - Product segments Exhibit 84: Mylan NV - Organizational developments Exhibit 85: Mylan NV - Geographic focus Exhibit 86: Mylan NV - Segment focus Exhibit 87: Mylan NV - Key offerings Exhibit 88: Mylan NV - Key customers Exhibit 89: Pfizer Inc. - Vendor overview Exhibit 90: Pfizer Inc. - Business segments Exhibit 91: Pfizer Inc. - Organizational developments Exhibit 92: Pfizer Inc. - Geographic focus Exhibit 93: Pfizer Inc. - Segment focus Exhibit 94: Pfizer Inc. - Key offerings Exhibit 95: Pfizer Inc. - Key customers Exhibit 96: Sanofi - Vendor overview Exhibit 97: Sanofi - Business segments Exhibit 98: Sanofi - Organizational developments Exhibit 99: Sanofi - Geographic focus Exhibit 100: Sanofi - Segment focus Exhibit 101: Sanofi - Key offerings Exhibit 102: Sanofi - Key customers Exhibit 103: Sun Pharmaceutical Industries Ltd. - Vendor overview Exhibit 104: Sun Pharmaceutical Industries Ltd. - Business segments Exhibit 105: Sun Pharmaceutical Industries Ltd. - Organizational developments Exhibit 106: Sun Pharmaceutical Industries Ltd. - Geographic focus Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key offerings Exhibit 108: Sun Pharmaceutical Industries Ltd. - Key customers Exhibit 109: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 110: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 111: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 112: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 115: Validation techniques employed for market sizing Exhibit 116: Definition of market positioning of vendors

AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.